Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;30(4):570-576.
doi: 10.53854/liim-3004-12. eCollection 2022.

Prognostic evaluation of Acinetobacter baumannii ventilator-associated pneumonia in COVID-19

Ilaria De Benedetto  1 , Tommaso Lupia  2 , Nour Shbaklo  1 , Alessandro Bianchi  3 , Erika Concialdi  4 , Maurizio Penna  4 , Silvia Corcione  1   5 , Francesco Giuseppe De Rosa  1   2
Affiliations

Prognostic evaluation of Acinetobacter baumannii ventilator-associated pneumonia in COVID-19

Ilaria De Benedetto et al. Infez Med. .

Abstract

Background: Since the emergence of the pandemic of SARS-CoV-2, a high reported incidence of VAP in COVID-19 sustained by carbapenem resistant Acinetobacter baumannii (CRAB) has been observed, but data are scarce to date.

Materials and methods: We retrospectively collected COVID-19 patients who developed CRAB-VAP - defined according to Center for Diseases Control (CDC) 2020 criteria and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) or Infectious Diseases Society of America (IDSA) guidelines - to describe characteristics and outcome.

Results: Among 21 patients with CRAB-VAP in COVID-19, median age was 66 years (IQR 41-80). Median time of VAP-onset was 7 days (IQR 0-28 days) from ICU - admission and 76.2% had septic shock. Treatment regimens were all colistin-based, in 28% (n=6) including ampicillin/sulbactam and rifampicin. In three cases, cefiderocol was started as rescue. Survival rate at 28-days was 35% (n=7).

Conclusion: Non-fermenting Gram-negative bacteria are an emerging aetiology of VAP in COVID-19 patients. This underscores the urgent need for proper microbiological identification to address therapies and infection control protocols.

Keywords: Acinetobacter baumannii; COVID-19; ICU; SARS-CoV-2; VAP.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest None to declare. Funding information No competing interest to disclose.

Similar articles

See all similar articles

Cited by

References

    1. American Thoracic Society. Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416. - PubMed
    1. Reignier J, Mercier E, Le Gouge A, et al. Clinical Research in Intensive C, Sepsis G. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. JAMA. 2013;309:249–256. - PubMed
    1. Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EUVAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36(11):1999–2006. - PubMed
    1. Seguin P, Laviolle B, Dahyot-Fizelier C, et al. Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter, randomized controlled trial. Crit Care Med. 2014;42:1–8. - PubMed
    1. Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888–906. - PMC - PubMed

LinkOut - more resources